ENPP1 and hyperinsulinemic hypoglycemia, familial, 4: Subcutaneous administration of the ENPP1-based biologic normalizes plasma PPi levels in patients with both ENPP1 and ABCC6 deficiency, but with a dose dependence unique to the underlying genetic cause (https://investors.inozyme.com/events-presentations).